Connective and Soft Tissue Neoplasm

Observed

← altered in cohorts of

TP53

167 / 261 cases (64 %) · ssm · TCGA-SARC · largest of 4 cohorts

—

Observed

← altered in cohorts of

RB1

165 / 261 cases (63 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ITM2B

154 / 261 cases (59 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

LPAR6

154 / 261 cases (59 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

RCBTB2

154 / 261 cases (59 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CAB39L

153 / 261 cases (59 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CDADC1

152 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CYSLTR2

152 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

FNDC3A

152 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

MLNR

152 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SETDB2

152 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

MED4

151 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

NUDT15

151 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PHF11

151 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

RCBTB1

151 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SUCLA2

151 / 261 cases (58 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ARL11

150 / 261 cases (57 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

KCNRG

150 / 261 cases (57 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

EBPL

149 / 261 cases (57 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

KPNA3

149 / 261 cases (57 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

TRIM13

149 / 261 cases (57 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SPRYD7

148 / 261 cases (57 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

HTR2A

147 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

DLEU7

146 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ESD

146 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

LRCH1

146 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

LCP1

145 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

RUBCNL

145 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SIAH3

145 / 261 cases (56 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

C13orf42

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CBY2

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CPB2

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ERICH6B

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

GPALPP1

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

LRRC63

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

RNASEH2B

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SLC25A30

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

TPT1

144 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

COG3

143 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

GTF2F2

143 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

KCTD4

143 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

NUFIP1

143 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ZC3H13

143 / 261 cases (55 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

DNAJC15

141 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

EPSTI1

141 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

FAM124A

141 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

INTS6

141 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SERPINE3

141 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

KLHL1

140 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PCDH17

140 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SERP2

140 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

SMIM2

140 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

TSC22D1

140 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

WDFY2

140 / 261 cases (54 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

AKAP11

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ALG11

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

BORA

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CCDC122

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CDKN2A

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CDKN2B

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CKAP2

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

DIS3

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

KLF5

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

LMO7

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

MZT1

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

OLFM4

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PIBF1

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PRR20A

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PRR20B

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PRR20C

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PRR20D

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PRR20E

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

TBC1D4

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

THSD1

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

TNFSF11

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

VPS36

139 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ATP7B

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

COMMD6

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

DOCK8

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

ENOX1

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

FAM216B

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

KLF12

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

LACC1

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

MYH10

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

NEK3

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

NEK5

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PCDH9

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

UCHL3

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

UTP14C

138 / 261 cases (53 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

DHRS12

137 / 261 cases (52 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

FREM2

137 / 261 cases (52 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

HNRNPA1L2

137 / 261 cases (52 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PCDH20

137 / 261 cases (52 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

PCDH8

137 / 261 cases (52 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

VWA8

137 / 261 cases (52 %) · ssm · TCGA-SARC

—

Observed

← altered in cohorts of

CSDE1

26 / 179 cases (15 %) · ssm · gist_msk_2025

—

Observed

← altered in cohorts of

SETD2

21 / 183 cases (11 %) · ssm · gist_msk_2025

—

Observed

← altered in cohorts of

PDGFRA

49 / 499 cases (9.8 %) · ssm · gist_msk_2022 · largest of 2 cohorts

—

Observed

← altered in cohorts of

CRIPAK

27 / 277 cases (9.7 %) · ssm · lipo_msk_2026

—

Liposarcoma

Observed

← altered in cohorts of

ZFHX3

20 / 277 cases (7.2 %) · ssm · lipo_msk_2026

—

Liposarcoma

Observed

Connective and Soft Tissue Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 201show all (up to 200)
→ investigated in trials for	Doxorubicinsmall molecule 96 trials (16 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	96	Observed	clinicaltrials	graph →
→ investigated in trials for	Ifosfamidesmall molecule 65 trials (8 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 57 trials (11 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 54 trials (3 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 42 trials (8 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinib Mesylatesmall molecule 41 trials (3 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 38 trials (3 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinibsmall molecule 30 trials (10 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 28 trials (17 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 27 trials (7 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 26 trials (2 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 26 trials (2 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 24 trials (5 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Regorafenibsmall molecule 22 trials (5 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 21 trials (1 active) · roll-up of the cancer and its descendants	—	—	Connective and Soft Tissue Neoplasm	21	Observed	clinicaltrials	graph →

Connective and Soft Tissue Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 201show all (up to 200)

→ investigated in trials for

Doxorubicinsmall molecule

96 trials (16 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ifosfamidesmall molecule

65 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

57 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

54 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

42 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinib Mesylatesmall molecule

41 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

38 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imatinibsmall molecule

30 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

28 trials (17 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

27 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

26 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

26 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

24 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Regorafenibsmall molecule

22 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

21 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Connective and Soft Tissue Neoplasm studied in …STUDIED_INderived10 of 1,966show all (up to 200)
→ studied in	NCT01109394recruiting Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Sarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02923778Phase 2 · active not recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Liposarcoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03759717recruiting Molecular and Cellular Characterization of Skull Base Tumors · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Skull Base Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04924075Phase 2 · recruiting Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) · condition mapped CURATED_BROADER · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06441331Phase 1 · recruiting Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors · condition mapped ALIAS · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07585266Phase 3 · recruiting A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · condition mapped ALIAS · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04145518Phase 4 · completed Mechanistic Characterization of Uterine Pain · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Leiomyoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04616560Phase 2 · recruiting Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Desmoplastic Small Round Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07837271active not recruiting Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →

Connective and Soft Tissue Neoplasm studied in …STUDIED_INderived10 of 1,966show all (up to 200)

→ studied in

NCT01109394recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Observed

→ studied in

NCT02923778Phase 2 · active not recruiting

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Liposarcoma

Observed

→ studied in

NCT03759717recruiting

Molecular and Cellular Characterization of Skull Base Tumors · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Skull Base Neoplasm

Observed

→ studied in

NCT04924075Phase 2 · recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) · condition mapped CURATED_BROADER · 1,966 trials mapped (518 active)

—

Observed

→ studied in

NCT06441331Phase 1 · recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors · condition mapped ALIAS · 1,966 trials mapped (518 active)

—

Observed

→ studied in

NCT07124000recruiting

DESTINY-PANTUMOUR04 · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Observed

→ studied in

NCT07585266Phase 3 · recruiting

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · condition mapped ALIAS · 1,966 trials mapped (518 active)

—

Observed

→ studied in

NCT04145518Phase 4 · completed

Mechanistic Characterization of Uterine Pain · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Leiomyoma

Observed

Desmoplastic Small Round Cell Tumor

→ studied in

NCT04616560Phase 2 · recruiting

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Observed

→ studied in

NCT07837271active not recruiting

Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST · condition mapped ONTOLOGY_EXACT · 1,966 trials mapped (518 active)

—

Observed